Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Clinical trial NCT06263491 · RECRUITING
Trial details
- NCT number
- NCT06263491
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-29
- Primary completion
- 2026-11-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.